2023
DOI: 10.1016/j.redox.2023.102881
|View full text |Cite
|
Sign up to set email alerts
|

Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood

Marilena M. Bourdakou,
Raquel Fernández-Ginés,
Antonio Cuadrado
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 68 publications
0
2
0
Order By: Relevance
“…NRF2 activators have been extensively studied in preclinical settings; however, which compounds to proceed with in VCID clinical trials is hard to determine. Five candidate compounds (curcumin, trichostatin-a, panobinostat, parthenolide, and entinostat) have been identified for AD treatment based on structural similarities, NRF2-diseasome, targeted pathways, and modes [237]. A selected list of NRF2 activators that are currently being trialed in CNS diseases is listed in Table 1.…”
Section: Future Perspectives On Nrf2 In Vcidmentioning
confidence: 99%
“…NRF2 activators have been extensively studied in preclinical settings; however, which compounds to proceed with in VCID clinical trials is hard to determine. Five candidate compounds (curcumin, trichostatin-a, panobinostat, parthenolide, and entinostat) have been identified for AD treatment based on structural similarities, NRF2-diseasome, targeted pathways, and modes [237]. A selected list of NRF2 activators that are currently being trialed in CNS diseases is listed in Table 1.…”
Section: Future Perspectives On Nrf2 In Vcidmentioning
confidence: 99%
“…Indeed, excessive oxidative stress levels are correlated with neuronal apoptosis and abnormal cerebral functioning, as demonstrated in individuals diagnosed with middle to advanced AD stages. , Consequently, the manipulation of damaged cell function from an upstream perspective represents a novel therapeutic approach with significant implications for long-term AD treatment. , Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a pivotal role in maintaining cellular redox homeostasis and remains inactive under normal conditions. ,, Upon exposure to external oxidative stress, Nrf2 is activated and translocated to the nucleus, triggering the transcription of downstream antioxidant proteins that safeguard cells against oxidative damage. However, persistent overactivation of Nrf2 can facilitate tumorigenesis by reprogramming a wide range of cancer metabolic pathways. , Hence, precise modulation of Nrf2-mediated signaling holds promise for long-term therapeutic intervention in AD. ,, …”
mentioning
confidence: 99%